why choose us

First received: June 20, 2023

Clinical Trial: BESPONSA Injection 1 mg Special Investigation

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Acute Lymphocytic Leukemia

Study Type: OBSERVATIONAL


Official Title: BESPONSA® INJECTION 1 MG SPECIAL INVESTIGATION

Brief Summary: The purpose of this study is to learn about the safety and effectiveness of BESPONSA.BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia.Registration criteria for this study is all patients who starting BESPONSA from its launch to the market to April 30, 2020.All patients in this study will receive BESPONSA according to the prescriptions.Patients will be followed up as follow.52 weeks for patients who did not have a HSCT (Hematopoietic Stem Cell Transplant) within…

Read more